Non-coding RNAs Underlying the Pathophysiological Links Between Type 2 Diabetes and Pancreatic Cancer: A Systematic Review

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2021 Dec 3

PMID 34859606

Citations 4

Authors

Fariba Dehghanian

Zahra Azhir

Sheyda Khalilian

Bjorn Gruning

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes is known as a risk factor for pancreatic cancer (PC). Various genetic and environmental factors cause both these global chronic diseases. The mechanisms that define their relationships are complex and poorly understood. Recent studies have implicated that metabolic abnormalities, including hyperglycemia and hyperinsulinemia, could lead to cell damage responses, cell transformation, and increased cancer risk. Hence, these kinds of abnormalities following molecular events could be essential to develop our understanding of this complicated link. Among different molecular events, focusing on shared signaling pathways including metabolic (PI3K/Akt/mTOR) and mitogenic (MAPK) pathways in addition to regulatory mechanisms of gene expression such as those involved in non-coding RNAs (miRNAs, circRNAs, and lncRNAs) could be considered as powerful tools to describe this association. A better understanding of the molecular mechanisms involved in the development of type 2 diabetes and pancreatic cancer would help us to find a new research area for developing therapeutic and preventive strategies. For this purpose, in this review, we focused on the shared molecular events resulting in type 2 diabetes and pancreatic cancer. First, a comprehensive literature review was performed to determine similar molecular pathways and non-coding RNAs; then, the final results were discussed in more detail.

Citing Articles

The Link between Diabetes, Pancreatic Tumors, and miRNAs-New Players for Diagnosis and Therapy?.

Kozlowska M, Sliwinska A Int J Mol Sci. 2023; 24(12).

PMID: 37373398 PMC: 10299694. DOI: 10.3390/ijms241210252.

Circular RNA hsa_circ_0004689 (circSWT1) promotes NSCLC progression via the miR-370-3p/SNAIL axis by inducing cell epithelial-mesenchymal transition (EMT).

Long X, Wang D, Wu Z, Liao Z, Xu J Cancer Med. 2022; 12(7):8289-8305.

PMID: 36530171 PMC: 10134258. DOI: 10.1002/cam4.5527.

Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.

Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu-Spinu I, Greabu M Int J Mol Sci. 2022; 23(17).

PMID: 36077529 PMC: 9456549. DOI: 10.3390/ijms231710132.

Non-coding RNAs underlying the pathophysiological links between type 2 diabetes and pancreatic cancer: A systematic review.

Dehghanian F, Azhir Z, Khalilian S, Gruning B J Diabetes Investig. 2021; 13(3):405-428.

PMID: 34859606 PMC: 8902405. DOI: 10.1111/jdi.13727.

References

Haque S, Harries L . Circular RNAs (circRNAs) in Health and Disease. Genes (Basel). 2017; 8(12). PMC: 5748671. DOI: 10.3390/genes8120353. View

Wang X, Xu Y, Zhu Y, Wang Y, Li J, Li X . LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy. J Cell Physiol. 2018; 234(8):12926-12933. DOI: 10.1002/jcp.27959. View

Ma L, Wang F, Du C, Zhang Z, Guo H, Xie X . Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Oncol Rep. 2018; 39(3):1132-1140. DOI: 10.3892/or.2018.6178. View

Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T . The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep. 2015; 35(3):1582-92. DOI: 10.3892/or.2015.4496. View

Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y . Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene. 2018; 673:181-193. DOI: 10.1016/j.gene.2018.06.037. View

Sun G, Kashyap S . Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab. 2011; 2011:708183. PMC: 3136221. DOI: 10.1155/2011/708183. View

Andersen G, Tost J . Circulating miRNAs as Biomarker in Cancer. Recent Results Cancer Res. 2019; 215:277-298. DOI: 10.1007/978-3-030-26439-0_15. View

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

Gao Z, Wang J, Chen D, Ma X, Wu Y, Tang Z . Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci. 2017; 7:66. PMC: 5715988. DOI: 10.1186/s13578-017-0192-0. View

10.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

11.

Childs E, Chaffee K, Gallinger S, Syngal S, Schwartz A, Cote M . Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev. 2016; 25(7):1185-91. PMC: 5321211. DOI: 10.1158/1055-9965.EPI-15-1217. View

12.

Stoll L, Sobel J, Rodriguez-Trejo A, Guay C, Lee K, Veno M . Circular RNAs as novel regulators of β-cell functions in normal and disease conditions. Mol Metab. 2018; 9:69-83. PMC: 5870096. DOI: 10.1016/j.molmet.2018.01.010. View

13.

Johnson J, Bowker S, Richardson K, Marra C . Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011; 54(9):2263-71. DOI: 10.1007/s00125-011-2242-1. View

14.

Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View

15.

Wu C, Yang L, Qi X, Wang T, Li M, Xu K . Inhibition of long non-coding RNA HOTAIR enhances radiosensitivity via regulating autophagy in pancreatic cancer. Cancer Manag Res. 2018; 10:5261-5271. PMC: 6223333. DOI: 10.2147/CMAR.S174066. View

16.

Ge X, Xu B, Xu W, Xia L, Xu Z, Shen L . Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression. Aging (Albany NY). 2019; 11(20):8745-8759. PMC: 6834398. DOI: 10.18632/aging.102249. View

17.

Ma L, Tian X, Guo H, Zhang Z, Du C, Wang F . Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. J Cancer. 2018; 9(2):389-399. PMC: 5771346. DOI: 10.7150/jca.21347. View

18.

. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831. PMC: 5611790. DOI: 10.1158/2159-8290.CD-17-0151. View

19.

Abbaszadeh-Goudarzi K, Radbakhsh S, Pourhanifeh M, Khanbabaei H, Davoodvandi A, Fathizadeh H . Circular RNA and Diabetes: Epigenetic Regulator with Diagnostic Role. Curr Mol Med. 2020; 20(7):516-526. DOI: 10.2174/1566524020666200129142106. View

20.

Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak M, Dunne R . Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020; 29(8):1586-1595. PMC: 7415636. DOI: 10.1158/1055-9965.EPI-19-1315. View